Thyrocare Technologies (BOM:539871) FFO

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BOM:539871 Thyrocare Technologies Ltd BOM:539871
87 GF Score
Price ₹599.95
GF Value ₹416.05
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is Thyrocare Technologies FFO?

FFO (Funds from operations) only applies to REITs.

BOM:539871
87GF Score
Thyrocare Technologies Ltd BOM:539871
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Thyrocare Technologies (BOM:539871) Overvalued in 2026?

Based on GuruFocus' analysis, Thyrocare Technologies stock appears to be overvalued. The current stock price of ₹599.95 is trading 44.2% above its estimated GF Value™ of ₹416.05. GuruFocus considers Thyrocare Technologies to be Significantly Overvalued.

Key valuation signals for BOM:539871:

  • FFO:
  • GF Value™: ₹416.05 vs. price of ₹599.95 (44.2% above fair value)
  • GF Score™: 87/100 with 5 warning signs

No single metric tells the full story. See the BOM:539871 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Thyrocare Technologies Business Description

Other Exchanges THYROCARE:India
Address D-37/3, TTC Industrial Area, MIDC, Turbhe, Opposite Sandoz, Navi Mumbai, MH, IND, 400703
Thyrocare Technologies Ltd is a diagnostics & research company. The company has three business segments: Diagnostic Testing Services, Imaging Services, and Others: Sale of testing equipment and consumables. The Diagnostic Testing Services segment provides Diagnostic and testing services, selling of consumables used for the collection and promotion of the pathology segment. The company majorly earns the majority of its revenue from the Diagnostic Testing Services segment. The Imaging Services segment operates Diagnostic and imaging services, selling of radio-pharmaceuticals, and selling of consumables for reporting. The Other business segment is engaged in the selling of glucometers and glucostrips under the brand name Sugarscan. The company earns the vast majority of its revenue in India.
87GF Score

Get the complete analysis for BOM:539871

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹599.95
Price
₹416.05
GF Value